9.055
Schlusskurs vom Vortag:
$8.66
Offen:
$8.57
24-Stunden-Volumen:
829.83K
Relative Volume:
0.68
Marktkapitalisierung:
$660.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-86.60M
KGV:
-3.1969
EPS:
-2.8324
Netto-Cashflow:
$-67.37M
1W Leistung:
-5.97%
1M Leistung:
+8.44%
6M Leistung:
+192.10%
1J Leistung:
+34.15%
Lexeo Therapeutics Inc Stock (LXEO) Company Profile
Firmenname
Lexeo Therapeutics Inc
Sektor
Branche
Telefon
(212) 547-9879
Adresse
345 PARK AVENUE SOUTH, NEW YORK
Vergleichen Sie LXEO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
LXEO
Lexeo Therapeutics Inc
|
9.055 | 632.07M | 0 | -86.60M | -67.37M | -2.8324 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lexeo Therapeutics Inc Stock (LXEO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-10-15 | Eingeleitet | Guggenheim | Buy |
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-13 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-06-06 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-11-28 | Eingeleitet | Chardan Capital Markets | Buy |
| 2023-11-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-28 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-28 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-11-28 | Eingeleitet | Stifel | Buy |
Alle ansehen
Lexeo Therapeutics Inc Aktie (LXEO) Neueste Nachrichten
Lexeo Therapeutics (Nasdaq: LXEO) plans virtual PKP2-ACM event at 22nd CVCT Forum Dec. 9 - Stock Titan
Why Lexeo Therapeutics Inc. stock remains resilientWeekly Stock Summary & Accurate Buy Signal Alerts - Newser
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Trading Down 7.8%What's Next? - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
How resilient is Lexeo Therapeutics Inc. stock in market downturnsJuly 2025 Analyst Calls & Safe Entry Point Alerts - Newser
Lexeo Therapeutics stock undervalued, Cantor Fitzgerald reiterates $19 target By Investing.com - Investing.com Canada
Will Lexeo Therapeutics Inc. stock deliver shareholder valueExit Point & Consistent Income Trade Ideas - moha.gov.vn
Why Lexeo Therapeutics Inc. stock is a must watch in 2025July 2025 Patterns & Expert Approved Momentum Ideas - BỘ NỘI VỤ
Paradigm Biocapital Advisors LP Acquires Significant Stake in Le - GuruFocus
LXEO Stock Price and Chart — NASDAQ:LXEO - TradingView
Research Analysts Set Expectations for LXEO FY2025 Earnings - MarketBeat
Savant Capital LLC Invests $119,000 in Lexeo Therapeutics, Inc. $LXEO - MarketBeat
Insider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 1,127 Shares of Stock - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock By Investing.com - Investing.com Australia
Lexeo Therapeutics CEO Makes Significant Stock Sale! - TipRanks
Balyasny Asset Management L.P. Increases Stake in Lexeo Therapeu - GuruFocus
[Form 4] Lexeo Therapeutics, Inc. Insider Trading Activity - Stock Titan
Adler, Lexeo Therapeutics CMO, sells $5.7k in LXEO stock - Investing.com
Lexeo Therapeutics CEO Sells Shares to Cover Tax Obligations - TradingView
CEO Townsend Surrenders 1,127 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Cantor Fitzgerald Initiates Coverage on Lexeo Therapeutics With Overweight Rating, $19 Price Target - MarketScreener
Equities Analysts Set Expectations for LXEO FY2025 Earnings - MarketBeat
Real time pattern detection on Lexeo Therapeutics Inc. stockMarket Activity Recap & Precise Entry and Exit Recommendations - newser.com
Using Ichimoku Cloud for Lexeo Therapeutics Inc. technicalsWeekly Market Summary & Real-Time Volume Triggers - newser.com
Will Lexeo Therapeutics Inc. price bounce be sustainableGold Moves & Daily Entry Point Alerts - newser.com
Using data models to predict Lexeo Therapeutics Inc. stock movementQuarterly Trade Review & Reliable Entry Point Alerts - newser.com
Officer Tai Files To Sell 386 Of Lexeo Therapeutics Inc [LXEO] - TradingView
Institutional Investors Are Lexeo Therapeutics, Inc.'s (NASDAQ:LXEO) Biggest Bettors and Were Rewarded After Last Week's US$70m Market Cap Gain - 富途牛牛
Lexeo Therapeutics Insiders Benefitted From Selling Stock At US$7.01 - simplywall.st
Optimistic Buy Rating for Lexeo Therapeutics Driven by High-Dose Potential and Superior Safety Profile - TipRanks
V2Y Corporation Ltd Expands into Renewable Energy and Commodities - The Globe and Mail
Can Lexeo Therapeutics Inc. stock withstand economic slowdownWeekly Trend Summary & Stock Portfolio Risk Management - newser.com
Using data filters to optimize entry into Lexeo Therapeutics Inc.Portfolio Risk Report & Fast Exit and Entry Trade Guides - newser.com
Is Lexeo Therapeutics Inc. meeting your algorithmic filter criteriaTrade Risk Assessment & Fast Moving Stock Trade Plans - newser.com
Long term hold vs stop loss in Lexeo Therapeutics Inc.July 2025 Opening Moves & Entry and Exit Point Strategies - newser.com
Best data tools to analyze Lexeo Therapeutics Inc. stockQuarterly Trade Summary & Weekly Chart Analysis and Trade Guides - newser.com
Should you hold or exit Lexeo Therapeutics Inc. now2025 Fundamental Recap & Precise Trade Entry Recommendations - newser.com
How Lexeo Therapeutics Inc. stock reacts to bond yieldsJuly 2025 Movers & Weekly Chart Analysis and Guides - newser.com
Using Python tools to backtest Lexeo Therapeutics Inc. strategiesMarket Sentiment Summary & AI Based Trade Execution Alerts - newser.com
What to do if you’re stuck in Lexeo Therapeutics Inc.Market Activity Report & Real-Time Stock Price Movement Reports - newser.com
Is Lexeo Therapeutics Inc a good long term investmentStop Loss Placement Tips & Subscribe for Free Weekly Winners - earlytimes.in
Why hedge funds are buying Lexeo Therapeutics Inc. stock2025 Year in Review & Momentum Based Trading Ideas - newser.com
Finanzdaten der Lexeo Therapeutics Inc-Aktie (LXEO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexeo Therapeutics Inc-Aktie (LXEO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Adler Eric | Chief Medical Officer |
Nov 18 '25 |
Sale |
9.27 |
615 |
5,701 |
72,646 |
| See Tai Sandi | Chief Development Officer |
Nov 18 '25 |
Sale |
9.27 |
386 |
3,578 |
65,476 |
| Robertson Jenny | Chief Legal Officer |
Nov 18 '25 |
Sale |
9.27 |
549 |
5,089 |
68,381 |
| Otero Jose Manuel | Chief Technical Officer |
Aug 18 '25 |
Sale |
9.27 |
721 |
6,684 |
63,476 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):